NASDAQ · PACB
Healthcare · Medical - Devices
$1.23
Up+$0.12 (+9.76%)
Updated Aug 22, 2026, 12:44 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PACB closed at $1.23 after 20 trading sessions, down 9.56% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $1.26 | $1.32 | $1.22 | $1.23 | 4.76M |
| Aug 19, 2026 | $1.20 | $1.31 | $1.20 | $1.27 | 10.91M |
| Aug 18, 2026 | $1.19 | $1.205 | $1.12 | $1.14 | 4.82M |
| Aug 17, 2026 | $1.15 | $1.225 | $1.13 | $1.21 | 6.12M |
| Aug 14, 2026 | $1.15 | $1.18 | $1.125 | $1.15 | 3.93M |
| Aug 13, 2026 | $1.13 | $1.18 | $1.10 | $1.15 | 6.35M |
| Aug 12, 2026 | $1.15 | $1.16 | $1.07 | $1.11 | 13.3M |
| Aug 11, 2026 | $1.17 | $1.17 | $1.14 | $1.14 | 6.12M |
| Aug 10, 2026 | $1.16 | $1.19 | $1.12 | $1.15 | 7.84M |
| Aug 7, 2026 | $1.19 | $1.23 | $1.165 | $1.185 | 7.38M |
| Aug 6, 2026 | $1.30 | $1.31 | $1.15 | $1.165 | 14.53M |
| Aug 5, 2026 | $1.44 | $1.465 | $1.27 | $1.30 | 11.64M |
| Aug 4, 2026 | $1.44 | $1.47 | $1.41 | $1.44 | 6.4M |
| Aug 3, 2026 | $1.43 | $1.47 | $1.395 | $1.42 | 3.55M |
| Jul 31, 2026 | $1.47 | $1.48 | $1.39 | $1.40 | 3.14M |
| Jul 30, 2026 | $1.41 | $1.49 | $1.41 | $1.48 | 2.81M |
| Jul 29, 2026 | $1.38 | $1.47 | $1.38 | $1.40 | 7.34M |
| Jul 28, 2026 | $1.35 | $1.415 | $1.32 | $1.39 | 7.93M |
| Jul 27, 2026 | $1.36 | $1.41 | $1.34 | $1.36 | 6.75M |
| Jul 24, 2026 | $1.42 | $1.43 | $1.32 | $1.36 | 8.06M |
The latest Smart Investors Daily articles mentioning PACB.
PACB research
Company profile and research snapshot.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 11, 2026 | Barclays | Underweight | — |
| Apr 14, 2026 | Barclays | Underweight | — |
| Mar 6, 2026 | Barclays | Underweight | — |
| Dec 15, 2025 | Barclays | Equal-Weight | — |
| Nov 11, 2025 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
Yahoo · Aug 16, 2026
Pacific Biosciences of California (NASDAQ:PACB) reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference. Revenue increased s
Yahoo · Aug 14, 2026
PacBio’s second quarter was met with a negative market reaction, as sales and adjusted earnings per share both fell short of Wall Street’s expectations. Management attributed the underperformance to ongoing funding constraints in the U.S. academic and government sectors, as well as a transition period as customers validated the new SPRQ-Nx chemistry. CEO Mark Van Oene, newly appointed after Christian Henry’s departure, stated that “customer enthusiasm for SPRQ-Nx has remained strong since full l
SeekingAlpha · Aug 8, 2026
2026-08-08. The following slide deck was published by Pacific Biosciences of California, Inc.
Yahoo · Aug 6, 2026
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PACB.
